glp-1 cardiovascular outcomes 2025 news The Many Benefits of Drugs Bridging the gap between GLP1-receptor
Description
Russell et al., 2009
However, so far, no therapeutic drugs have been able to meet all these requirements, especially when it comes to improving fibrosis
Related article: How to Travel with GLP-1s: Everything You Need to Know For a Safe and Stress-Free Trip
Sept 6: AstraZeneca will have to wait to add another indication to the label of blockbuster drug Ultomiris, as the FDA rejected the companys supplemental application in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease particularly affecting the optic nerve
